Autophagy regulates MK-2206-induced LDL receptor expression and cholesterol efflux pathways

Area of Science:

• Cellular Biology
• Metabolic Disease Research

Background:

• Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease (CVD).
• Low-density lipoprotein (LDL) receptor (LDLR) activity is a key target for lipid-lowering therapies.
• Autophagy's role in lipid and cholesterol metabolism is an emerging area of research.

Purpose of the Study:

• To investigate the influence of autophagy on LDLR and ABCA1 expression in hepatocytes.
• To examine the effects of AKT inhibitors (MK-2206 and triciribine) on autophagy-related cholesterol metabolism.

Main Methods:

• Pharmacological inhibition of autophagy using SBI-0206965 and genetic disruption via siRNA targeting ATG5 and ATG7.
• Generation of stable knockout HAP1 cell lines for ATG5 and ATG7 using CRISPR.
• Quantitative analysis of ABCA1, LDLR, and autophagy marker (LC3B) expression at protein and mRNA levels.

Main Results:

• MK-2206 treatment increased hepatic LDLR and the autophagy marker LC3B.
• Inhibition of autophagy reduced MK-2206-induced LDLR upregulation by approximately 50-70%.
• Autophagy deficiency abolished ABCA1 expression and indicated involvement in cholesterol efflux regulation.

Conclusions:

• Autophagy plays a significant role in regulating cholesterol metabolism.
• Impairment of autophagy attenuates the LDLR-inducing effects of MK-2206.
• Autophagy is involved in regulating cholesterol efflux, with implications for CVD prevention.